Pfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment Council

South Dakota Investment Council raised its stake in Pfizer Inc. (NYSE:PFE) by 33.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,246,648 shares of the biopharmaceutical company’s stock after buying an additional 312,410 shares during the quarter. Pfizer comprises about 0.8% of South Dakota Investment Council’s portfolio, making the stock its 15th biggest holding. South Dakota Investment Council’s holdings in Pfizer were worth $35,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the stock. Wedge Capital Management L L P NC increased its stake in Pfizer by 10.6% during the third quarter. Wedge Capital Management L L P NC now owns 10,865 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 1,044 shares during the period. LMG Wealth Partners LLC increased its stake in Pfizer by 11.7% during the third quarter. LMG Wealth Partners LLC now owns 37,963 shares of the biopharmaceutical company’s stock worth $1,259,000 after purchasing an additional 3,990 shares during the period. Cardinal Capital Management increased its stake in Pfizer by 4.1% during the third quarter. Cardinal Capital Management now owns 30,329 shares of the biopharmaceutical company’s stock worth $1,006,000 after purchasing an additional 1,185 shares during the period. Bard Financial Services Inc. increased its stake in Pfizer by 9.7% during the third quarter. Bard Financial Services Inc. now owns 342,679 shares of the biopharmaceutical company’s stock worth $11,367,000 after purchasing an additional 30,235 shares during the period. Finally, MinichMacGregor Wealth Management LLC increased its stake in Pfizer by 29.5% during the third quarter. MinichMacGregor Wealth Management LLC now owns 7,961 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 1,815 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock traded up $0.06 during trading hours on Tuesday, hitting $26.32. The stock had a trading volume of 24,286,365 shares, compared to its average volume of 42,105,117. The firm has a market capitalization of $149.04 billion, a PE ratio of 73.11, a PEG ratio of 1.17 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The stock’s 50 day moving average is $27.08 and its 200 day moving average is $28.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.14 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.